In vitro model of mycobacteria and HIV-1 co-infection for drug discovery.
暂无分享,去创建一个
M. Ferguson | J. Cirillo | J. Endsley | Rebecca J. Nusbaum | O. Olaleye | Sudhamathi Vijayakumar | Sarah Finney John | Omonike A. Olaleye
[1] Robert L. Hunter,et al. A Humanized Mouse Model of Tuberculosis , 2013, PloS one.
[2] S. A. Abdool Karim,et al. When to start antiretroviral therapy during tuberculosis treatment? , 2013, Current opinion in infectious diseases.
[3] Gundo Weiler,et al. Global Update on HIV Treatment 2013: Results, Impact and Opportunities , 2013 .
[4] Philippe Glaziou,et al. Global tuberculosis control: lessons learnt and future prospects , 2012, Nature Reviews Microbiology.
[5] Hong Liang,et al. Antibacterial activities of gold and silver nanoparticles against Escherichia coli and bacillus Calmette-Guérin , 2012, Journal of Nanobiotechnology.
[6] D. Havlir,et al. HIV and tuberculosis – science and implementation to turn the tide and reduce deaths , 2012, Journal of the International AIDS Society.
[7] M. Marsden,et al. HIV Latency in the Humanized BLT Mouse , 2011, Journal of Virology.
[8] W. Baze,et al. Antibacterial Role for Natural Killer Cells in Host Defense to Bacillus anthracis , 2011, Infection and Immunity.
[9] Ning Zhang,et al. Whole‐Body Imaging of Infection Using Fluorescence , 2011, Current protocols in microbiology.
[10] D. Havlir,et al. Tuberculosis as part of the natural history of HIV infection in developing countries. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] M. Pai,et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] J. Richard,et al. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. , 2010, Blood.
[13] M. Wainberg,et al. Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice , 2010, PloS one.
[14] A. Hogg,et al. Induction of granulysin in CD8+ T cells by IL‐21 and IL‐15 is suppressed by human immunodeficiency virus‐1 , 2009, Journal of leukocyte biology.
[15] F. Kirchhoff,et al. Is Nef the elusive cause of HIV-associated hematopoietic dysfunction? , 2008, The Journal of clinical investigation.
[16] W. Waters,et al. Mycobacterium bovis BCG vaccination induces memory CD4+ T cells characterized by effector biomarker expression and anti-mycobacterial activity. , 2007, Vaccine.
[17] G. Maartens,et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. , 2007, The Journal of infectious diseases.
[18] A. Walubo. The role of cytochrome P450 in antiretroviral drug interactions. , 2007, Expert opinion on drug metabolism & toxicology.
[19] M. E. Villarino. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus; principles of therapy and revised recommendations , 1998 .
[20] A. Poggi,et al. HIV-1 Tat inhibits human natural killer cell function by blocking L-type calcium channels. , 1998, Journal of immunology.
[21] Y. Cao,et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. , 1997, American journal of respiratory and critical care medicine.
[22] D. Hom,et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. , 1995, American journal of respiratory and critical care medicine.
[23] H. Friedman,et al. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1 , 1992, Journal of virology.